An Open-Label Study to Evaluate the Efficacy and Safety Of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARDs and/or Biologic DMARDs
Phase of Trial: Phase IV
Latest Information Update: 07 Jul 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2014 Planned End Date changed from 1 May 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.